argenx's CD70 mAb leads to 92% response rate in AML

In an abstract released ahead of next month’s American Society of Hematology meeting, argenx S.E. (Euronext:ARGX; NASDAQ:ARGX) said cusatuzumab (ARGX-110) plus

Read the full 213 word article

User Sign In